CHMP issues positive opinion to expand INVOKANA & VOKANAMET labels

Shots: Mundipharma has gained exclusive distribution rights from Janssen for Europe and Switzerland excluding Spain The drug is recommended for Type 2 Diabetes Mellitus (T2DB) patients with adverse CV disease or atleast 2 CV risk factors The Type 2 variation application is based on CANVAS programme included 10,000 patients treated since 2009, showed reduction in […]Read More